NASDAQ : ORMP

Oramed Pharmaceuticals Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 4.23 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 175.96M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Details

NameOramed Pharmaceuticals Inc.
SectorHealthcare
IndustryBiotechnology
Employees4
Founded2002
CeoNadav Kidron
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS68403P2039
Cusip68403P203
Cik0001176309
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Nadav Kidron Esq.President, Chief Executive Officer and Executive Chairman
Joshua HexterChief Operating and Business Officer
Dr. Miriam Kidron Ph.D.Chief Scientific Officer and Director
Avraham GabayChief Financial Officer, Treasurer and Secretary

Contact

Address1185 Avenue of the Americas, Third Floor, New York, New York 10036, United States
Phone844 967 2633
Websitehttps://oramed.com